PTH analogues and osteoporotic fractures

Area of Science:

• Endocrinology
• Bone Metabolism
• Pharmacology

Background:

• Two parathyroid hormone (PTH) analogues, PTH 1-34 and PTH 1-84, are approved for treating established osteoporosis in postmenopausal women and men at high fracture risk.
• These analogues play a crucial role in managing bone density and skeletal integrity.

Purpose of the Study:

• To evaluate the efficacy and safety of PTH 1-34 and PTH 1-84 in osteoporosis management.
• To review data on fracture risk reduction and safety endpoints associated with PTH analogue therapy.

Main Methods:

• A comprehensive review of published literature and scientific meeting presentations up to 2010.
• Focus on studies detailing fracture risk reduction and adverse events.

Main Results:

• PTH analogues stimulate bone formation, increase bone mass and strength, and improve calcium balance.
• PTH 1-34 and PTH 1-84 reduced vertebral fracture risk in postmenopausal women; PTH 1-34 also reduced non-vertebral fractures.
• PTH 1-34 demonstrated efficacy in reducing vertebral fractures in men and women with glucocorticosteroid-induced osteoporosis.

Conclusions:

• Exogenous PTH analogues administered via daily subcutaneous injections are effective in treating osteoporosis.
• PTH analogues are well-tolerated, offering a favorable safety profile for fracture prevention and treatment in severe osteoporosis.
• PTH analogues represent a valuable therapeutic option for patients with established osteoporosis, particularly postmenopausal women.